Perrigo Company plc (PRGO) has received final approval from the U.S. Food & Drug Administration or FDA for its abbreviated new drug application or ANDA for repaglinide tablets 1 mg and 2 mg, the generic equivalent to Prandin Tablets and has commenced shipment of product. Earlier, Perrigo launched the 0.5 mg strength in 2013.
Prandin tablets, are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus and have annual sales of some $250 million, as measured by Symphony Health Solutions.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.